Basilea Pharmaceutica AG/Fr. BSLN
1D1W1MYTD1Y5YMAX
Capital at risk
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG operates within the biopharmaceutical industry, focusing on the research, development, and commercialization of innovative medicines to meet medical needs in the areas of infectious diseases and oncology. The company's core products include anti-infective treatments such as Cresemba, an antifungal for invasive aspergillosis and mucormycosis, and Zevtera, a broad-spectrum antibiotic for bacterial infections. Founded in 2000 as a spin-off from Roche, the company is headquartered in Basel, Switzerland. Basilea's unique strategic approach involves enhancing its pipeline through collaborations and licensing agreements, which strengthens its position in the niche market of bacterial resistance and other medical areas with high unmet needs. The company has a significant presence in Europe, the United States, and Asia, expanding its commercial footprint globally.
- Ticker
- Fr. BSLN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 200
- Headquarters
- Allschwil, Switzerland
- Website
- www.basilea.com
BSLN Metrics
BasicAdvanced
CHF 821M
16.51
CHF 4.01
0.41
-
Price and volume
Market cap
CHF 821M
Beta
0.41
52-week high
CHF 68.00
52-week low
CHF 44.70
Average daily volume
55K
Financial strength
Current ratio
6.596
Quick ratio
5.811
Long term debt to equity
0.501
Total debt to equity
0.514
Interest coverage (TTM)
21.08%
Profitability
EBITDA (TTM)
60.92
Gross margin (TTM)
38.51%
Net profit margin (TTM)
21.17%
Operating margin (TTM)
24.20%
Effective tax rate (TTM)
10.72%
Revenue per employee (TTM)
CHF 1,240,000
Management effectiveness
Return on assets (TTM)
13.69%
Return on equity (TTM)
39.46%
Valuation
Price to earnings (TTM)
16.508
Price to revenue (TTM)
3.292
Price to book
5.05
Price to tangible book (TTM)
5.06
Price to free cash flow (TTM)
14.78
Free cash flow yield (TTM)
6.77%
Free cash flow per share (TTM)
4.479
Growth
Revenue change (TTM)
4.74%
Earnings per share change (TTM)
-26.73%
3-year revenue growth (CAGR)
12.23%
10-year revenue growth (CAGR)
15.65%
3-year earnings per share growth (CAGR)
-3.53%
10-year earnings per share growth (CAGR)
-3.71%
Bulls say / Bears say
H1 2026 total revenue rose 14% to CHF 119.0 million, operating profit increased 32% to CHF 31.6 million and net profit rose 77% to CHF 27.9 million; Basilea consequently raised its full-year 2026 operating-profit growth guidance to approximately 40%. (Basilea)
Cresemba royalty income increased 10.9% year over year to CHF 57.8 million, and Basilea now expects Cresemba- and Zevtera-related revenue of approximately CHF 210 million in 2026, supporting an estimated CHF 180 million cash contribution from the commercial business. (Basilea)
Basilea received an additional USD 30 million from BARDA after meeting a prespecified enrollment milestone for fosmanogepix, providing non-dilutive funding for its phase 3 program and reducing the near-term financing burden of advancing the lead pipeline asset. (Basilea)
H1 2026 product revenue fell to CHF 29.9 million from CHF 31.5 million, while growth was driven more by royalties, BARDA-related revenue and other contract income; this mix may make reported performance more dependent on partners and non-recurring activities. (Basilea)
R&D expenses increased 41% year over year to CHF 54.0 million, while operating cash flow declined to CHF 19.0 million from CHF 23.1 million; continued pipeline investment could pressure cash conversion if development milestones are delayed. (Basilea)
Fosmanogepix data readout and regulatory submission are not expected until 2028, leaving substantial clinical, regulatory and execution risk before the program can contribute commercially; the newly licensed ceftibuten-ledaborbactam asset also remains development-stage. (Basilea)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Upcoming events
No upcoming events
Funds containing BSLN
AllEURGBPUSD
Fund name | Fund size | Fr. BSLN weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.06% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.06% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.